Management of anemia in cancer patients

Future Oncology

Volumn 7, Issue 4, 2011, Pages 507-517

  Calabrich, Aknar ^a,b   Katz, Artur ^b  

^a AMO Clinic   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

anemia; blood tranfusion; cancer; erythropoiesis stimulating agents; iron

Indexed keywords

ANTIANEMIC AGENT; CYTOKINE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CYTOKINE RELEASE; DEATH; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNE RESPONSE; IRON DEFICIENCY ANEMIA; IRON METABOLISM; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SOLID TUMOR; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE;

ANEMIA; ANTINEOPLASTIC AGENTS; HEMATINICS; HUMANS; NEOPLASMS;

EID: 79953688736     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.24     Document Type: Review

References (73)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl Cancer Inst. 91, 1616-1634 (1999). (Pubitemid 29479929)
2. WHO: Indicators and Strategies for Iron Defciency and Anemia Programmes. Report of the WHO/UNICEF/UNU Consultation, Swizerland (1994).
3. Ludwig H, Strasser K: Symptomatology of anemia. Semin. Oncol. 28, 7-14 (2001). (Pubitemid 32522231)
4. Vaupel P, Dunst J, Engert A et al.: Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 28, 216-221 (2005). (Pubitemid 41094492)
5. Zhao KL, Liu G, Jiang GL et al.: Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiothe rapy-a secondary analysis of three consecutive clinical Phase III trials. Clin. Oncol. (R. Coll. Radiol.) 18, 621-627 (2006). (Pubitemid 44309261)
6. Henry DH: Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent. Oncology (Williston Park) 16, 9-12 (2002).
7. Glaspy JA: The potential for anemia treatment to improve survival in cancer patients. Oncology (Williston Park) 16, 35-40 (2002).
8. Ludwig H, Van Belle S, Barrett-Lee P et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defning the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40, 2293-2306 (2004). (Pubitemid 39348881)
9. Ludwig H, Aapro M, Bokemeyer C et al.: Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: fndings from the Anaemia Cancer Treatment (ACT) st udy. Eur. J. Cancer 45, 1603-1615 (2009).
10. Glaspy JA: The development of erythropoietic agents in oncology. Expert Opin. Emerg Drugs 10, 553-567 (2005). (Pubitemid 41176287)
11. Adamson JW, Spivak JL: Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment. Surgery 115, 7-15 (1994). (Pubitemid 24039205)
12. Clark O, Adams JR, Bennett CL et al.: Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2, 23 (2002).
13. Ferrario E, Ferrari L, Bidoli P et al.: Treatment of cancer-related anemia with epoetin a: a review. Cancer Treat. Rev. 30, 563-575 (2004). (Pubitemid 39157855)
14. Beutel G, Ganser A: Risks and benefts of erythropoiesis-stimulating agents in cancer management. Semin. Hematol. 44, 157-165 (2007). (Pubitemid 47031226)
15. Fenner MH, Ganser A: Erythropoietin in cancer-related anemia. Curr. Opin. Oncol. 20, 685-689 (2008).
16. Bohlius J, Wilson J, Seidenfeld J et al.: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl Cancer Inst. 98, 708-714 (2006). (Pubitemid 43821788)
17. Marchal C, Rangeard L, Brunaud C: Anemia impact on treatments of cervical carcinomas. Cancer Radiother. 9, 87-95 (2005).
18. Dunst J: Management of anemia in patients undergoing curative radiotherapy Erythropoietin, transfusions, or better nothing? Strahlenther. Onkol. 180, 671-681 (2004). (Pubitemid 40022273)
19. Bohlius J, Langensiepen S, Schwarzer G et al.: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J. Natl Cancer Inst. 9 7, 489-498 (2005). (Pubitemid 40590430)
20. Bohlius J, Langensiepen S, Schwarzer G et al.: Erythropoietin for patients with malignant disease. Cochrane Database Syst. Rev. (3), CD003407 (2004).
21. Bohlius J, Wilson J, Seidenfeld J et al.: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. (3), CD007303 (2006).
22. Minton O, Richardson A, Sharpe M et al.: A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J. Natl Cancer Inst. 100, 1155-1166 (2008).
23. Littlewood TJ, Nortier J, Rapoport B et al.: Epoetin a corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol. Oncol. 21, 169-180 (2003). (Pubitemid 38146268)
24. Osterborg A, Brandberg Y, Molostova V et al.: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin b, in hematologic malignancies. J. Clin. Oncol. 20, 2486-2494 (2002). (Pubitemid 34525734)
25. Pronzato P, Cortesi E, van der Rijt CC et al.: Epoetin a improves anemia and anemia-related, patient-reported o utcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist 15, 935-943 (2008).
26. Bennett CL, Silver SM, Djulbegovic B et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299, 914-924 (2008). (Pubitemid 351397066)
27. Henke M, Laszig R, Rübe C et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260 (2003). (Pubitemid 37324251)
28. Hedenus M, Adriansson M, San Miguel J et al.: Effcacy and safety of darbepoetin a in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br. J. Haematol. 122, 394-403 (2003). (Pubitemid 36951623)
29. Leyland-Jones B, Semiglazov V, Pawlicki M et al.: Maintaining normal hemoglobin levels with epoetin a in mainly nonanemic patients with metastatic breast cancer receiving frst-line chemotherapy: a survival study. J. Clin. Oncol. 23, 5960-5972 (2005).
30. Wright JR, Ung YC, Julian JA et al.: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J. Clin. Oncol. 25, 1027-1032 (2007). (Pubitemid 46596751)
31. Smith RE Jr, Aapro MS, Ludwig H et al.: Darbepoetin a for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a P hase III, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 26, 1040-1050 (2008).
32. Thomas G, Ali S, Hoebers FJ et al.: Phase III trial to evaluate the effcacy of maintaining h emoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol. Oncol. 108, 317-325 (2008).
33. Overgaard J, Hoff C, Hansen HS: Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur. J. Cancer Suppl. 5, 7 (2007).
34. Bokemeyer C, Aapro MS, Courdi A et al.: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur. J. Cancer 40, 2201-2216 (2004). (Pubitemid 39348870)
35. Aapro M, Scherhag A, Burger HU: Effect of treatment with epoetin-b on survival, tumour progression and thromboembolic events in patients with cancer: an updat ed meta-analysis of 12 randomised controlled studies including 2301 patients. Br. J. Cancer 99, 14-22 (2008). (Pubitemid 351920217)
36. Tonelli M, Hemmelgarn B, Reiman T et al.: Benefts and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 180, E62-E71 (2009).
37. Bohlius J, Schmidlin K, Brillant C et al.: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 37 3, 1532-1542 (2009).
38. Bohlius J, Schmidlin K, Brillant C et al.: Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst. Rev. (3), CD007303 (2009).
39. Paladini L, Clark O, Clark L: Erythropoiesis stimulating agents (ESA) for the treatment of chemotherapy induced anemia in patient s with hemoglobin levels (Hb) <11g/dl-a systematic review and meta-analysis. Blood 112, Abstract 1305 (2008).
40. Ludwig H, Crawford J, Osterborg A et al.: Pooled analysis of individual patient-level data from a ll randomized, double-blind, placebo-controlled trials of darbepoetin a in the treatment of patients with chemotherapy-induced anemia. J. Clin. Oncol. 27, 2838-2847 (2009).
41. Strauss HG, Haensgen G, Dunst J et al.: Effects of anemia correction with epoetin b in patients receiving radiochemotherapy for advanced cervical cancer. Int. J. Gynecol. Cancer 18, 515-524 (2008). (Pubitemid 351668300)
42. Aapro M, Spivak JL: Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 14(Suppl. 1), 6-15 (2009).
43. Bokemeyer C, Aapro MS, Courdi A et al.: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur. J. Cancer 43, 258-270 (2007). (Pubitemid 46127840)
44. Nowrousian MR, Dunst J, Vaupel P: Erythropoiesis-stimulating agents: favorable safety profle when used as indicated. Strahlenther. Onkol. 184, 121-136 (2008). (Pubitemid 351365785)
45. Rizzo JD, Brouwers M, Hurley P et al.: American Society of Clinical Oncology/American Society of Hematology Clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J. Clin. Oncol. 28, 4996-5010 (2010).
46. Lyman GH, Glaspy J: Are there clinical benefts with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 106, 223-233 (2006). (Pubitemid 43032569)
47. Theurl I, Mattle V, Seifert M et al.: Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 107, 4142-4148 (2006). (Pubitemid 43726825)
48. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of infammation. Blood 102, 783-788 (2003). (Pubitemid 36917762)
49. Truksa J, Peng H, Lee P, Beutler E: Different regulatory elements are required for response of hepcidin to interleukin-6 and bone morphogenetic proteins 4 and 9. Br. J. Haematol. 139, 138-147 (2007). (Pubitemid 47389916)
50. Chen YM, Whang-Peng J, Liu JM et al.: Serum cytokine level fuctuations in chemotherapy-induced myelosuppression. Jpn J. Clin. Oncol. 26, 18-23 (1996). (Pubitemid 126469261)
51. Hedenus M, Birgegard G: The role of iron supplementation during epoietin treatment for cancer-related anemia. Med. Oncol. 26, 105-115 (2009).
52. Henry DH, Dahl NV: Iron and B12 parameters in anemic cancer patients on chemotherapy presenting for epoetin a (EPO) therapy. J. Clin. Oncol. 14(Suppl.), Abstract 8091 (2004).
53. Chertow GM, Mason PD, Vaage-Nilsen O et al.: Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 21, 378-382 (2006). (Pubitemid 43159991)
54. Auerbach M, Balla rd H, Trout JR et al.: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22, 1301-1307 (2004). (Pubitemid 41079845)
55. Henry DH, Dahl NV, Auerbach M et al.: Intravenous ferric gluconate signifcantly improves response to epoetin a versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12, 231-242 (2007).
56. Bellet RE, Ghazal H, Flam M et al.: A Phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing ch emotherapy and erythropoietin stimulating agent (ESA) therapy. J. Clin. Oncol. 18(Suppl.), Abstract 9109 (2007).
57. Hedenus M, Birgegard G, Nasman P et al.: Addition of intravenous iron to epoetin b increases hemogl obin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study Leukemia 21, 627-632 (2007). (Pubitemid 46444544)
58. Beguin Y, Maertens J, De Prijck B et al.: Darbepoetin-a and I.V. iron administration after autologous hematopoietic stem cell transplantation: a prospective randomized multicenter trial. Blood (ASH Annual Meeting Abstracts) 112, Abstract 54 (2008).
59. Bastit L Vandebroek A, Altintas S et al.: Randomized, multicenter, controlled trial comparing the effcacy and safety of darbepoetin a administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 26, 1611-1618 (2008).
60. Pedrazzoli P, Farris A, Del Prete S et al.: Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron defciency treated w ith darbepoetina. J. Clin. Oncol. 26, 1619-1625 (2008).
61. Auerbach M, Silberstein PT, Webb RT et al.: Darbepoetin a 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemot herapy-induced anemia. Am. J. Hematol. 85, 655-663 (2010).
62. Steensma DP, Sloan JA, Dakhil SR et al.: Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementati on on the erythropoietic response to darbepoetin a for patients with chemotherapy- associated anemia. J. Clin. Oncol. 29, 97-105 (2011).
63. Gafter-Gvili A, Rozen-Zvi B, Vidal L et al.: Intravenous iron supplementation for the treatment of cancer-related anemia-systematic review and meta-analysis. Blood (ASH Annual Meeting Abstracts) 116, Abstract 4249 (2010).
64. Mhaskar R, Wao H, Kumar A et al.: Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients: a systematic review and meta-analysis. Blood (ASH Annual Meeting Abstracts) 116, Abstract 2055 (2010).
65. Thomas ML: Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Med. Oncol. 15(Suppl. 1), S13-S18 (1998). (Pubitemid 28429598)
66. Barrett-Lee PJ, Bailey NP, O'Brien ME et al.: Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br. J. Cancer 82, 93-97 (2000). (Pubitemid 30008965)
67. Leibovitz A, Baumoehl Y, Walach N et al.: Medical staff attitudes: views and positions regarding blood transfusion to terminally ill cancer patients. Am. J. Clin. Oncol. 27, 542-546 (2004). (Pubitemid 39371955)
68. Kader AS, Lim JT, Berthelet E et al.: Prognostic signifcance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy Am. J. Clin. Oncol. 30, 492-497 (2007). (Pubitemid 47537949)
69. Atzil S, Arad M, Glasner A et al.: Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology 109, 989-997 (2008).
70. Fyles AW, Milosevic M, Pintilie M et al.: Anemia, hypoxia and transfusion in patients with cervix cancer: a review. Radiother. Oncol. 57, 13-19 (2000).
71. Khorana AA, Francis CW, Blumberg N et al.: Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch. Intern. Med. 168, 2377-2381 (2008).
72. Spivak JL, Gascon P, Ludwig H: Anemia management in oncology and hematology Oncologist 14(Suppl. 1), 43-56 (2009).
73. Dicato M, Plawny L, Diederich M: Anemia in cancer. Ann. Oncol. 21(Suppl. 7), VII167-VII172 (2010).